New Clinical Trial at ACTU
Study: Bone Loss in People With HIV
March 26, 2004
The study is a Phase II, randomized, double-blinded, placebo-controlled study of once-weekly Alendronate in HIV-infected subjects with decreased bone mineral density receiving calcium and vitamin D. (Alendronate is an FDA-approved drug to treat osteoporosis. Its use in this study is experimental.)
TreatmentThe study will provide the following combinations:
CompensationExams, lab tests, and study medications at no cost. $20 per study visit and $25 for each DEXA scan while on study. Contact the ACTU (206) 731-3184 and ask for the screening nurse on call.
To see a complete list of clinical trials at the ACTU visit our Web site at http://depts.washington.edu/actu or call (206) 731-3497 and ask for the Outreach Coordinator, Joaquin Perez or Alyssa Spingola RN at (206) 731-8876.
This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.